A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy

Type of Cancer

Warning: implode(): Invalid arguments passed in /home/region33/public_html/wp-content/themes/regionalcancercenter/single-clinical-trials.php on line 42
Locations
Sponsor
Bristol-Myers Squibb
Protocol Number
Bristol Myers Squibb CA209-040
Cancer Diagnosis
To Learn More Call
201-510-0910